Inclusion Criteria:

- Participants must have histologically or cytologically confirmed invasive or in-situ
carcinoma of the breast

- Participants must have undergone sentinel lymph node mapping or axillary dissection

- Participants must have had a pre-operative Perometer measurement, and consecutive
measurement at 4-6 month intervals prior to the onset of low volume edema (>5% from
baseline)

- Age > 18 years

- Life expectancy of greater than 1 year

- Participants must have a Perometer measurement of 5% or greater volume difference
(RVC) to qualify for randomization

- Ability to understand and willingness to sign a written informed consent document

- Willingness to comply with required follow up Perometer measurements and clinical
visits

Exclusion Criteria:

- Known metastatic disease or other locally advanced disease in the thoracic or
cervical regions

- Any patient who will not be returning routinely for follow-up

- Known brain metastases will be excluded from this clinical trial because of their
poor prognosis and because they often develop progressive neurologic dysfunction that
would confound the evaluation of neurologic and other adverse events

- History of primary lymphedema

- History of prior surgery or radiation to the head, neck, upper limb, or trunk

- Evidence that axillary lymph node malignancy is causing lymphedema due to recurrence
as per physician discretion

- Any patient who has bilateral lymph node mapping or dissection

- Any patient with a current case of cellulitis

- Patients with a history of a different malignancy are ineligible except for the
following circumstances. Individuals with a history of other malignancies are
eligible if they have been disease-free for at least 5 years and are deemed by the
investigator to be at low risk for recurrence of that malignancy. Individuals with
the following cancer are eligible if diagnosed and treated within the past 5 years:
cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin